Combat Medical #HIVEC #HIPEC

In primary ovarian cancer, HIPEC + interval cytoreductive surgery + neoadjuvant chemotherapy was found to be a safe option that significantly improved 5-year overall survival and disease-free survival in a 2022 systematic review and meta-analysis. #ovariancancerawarenessmonth

We’re building the foundation for ovarian cancer treatment with Combat PRS+ HIPEC in South Africa, where it will soon be offered at the Chris Hani Baragwanath Academic Hospital in Johannesburg. #ovariancancerawarenessmonth #HIPEC #CombatCancer

Yesterday, we were in Parliament to mark #OvarianCancerAwarenessMonth this March. We were delighted that the Minister for Public Health & Prevention, @SharonHodgsonMP, joined us to speak with our brilliant campaigners - Sbba, Sue, Reeta and Natalie. (1/2)

Cancer drugs may fail because they’re unevenly distributed inside tumours. New research shows PARP inhibitors – used in ovarian cancer treatment – can form lysosomal “reservoirs,” potentially driving resistance. 👉bit.ly/4uxArZP #ovariancancerawarenessmonth #CombatCancer

📣 Results from WBCPC Global Survey! 🗣️ “Joining a support group is the best way to connect with others who have been through the same experience as you, or are going through it too.” The report👉 ow.ly/pa8H50OQmXA

Type 2 diabetes slightly increases the risk of ovarian cancer from 2% in the overall population to 2.4% in women with type 2. Antidiabetic medications like metformin have shown promise in improving prognosis and survival. #ovariancancerawarenessmonth #HIPEC #CombatCancer

Thank you to everyone who came to see us at #EAU2026! Great to spread the word about our phase 3 DA-approved trial, #HIVEC®-HEAT, which aims to provide an alternative to radical cystectomy in BCG-unresponsive patients with NMIBC. #CombatCancer

💥Day 1 at #EAU2026! 👉 Visit us at Booth J22 to learn more our FDA-approved trial, HIVEC®-HEAT. It aims to provide an affordable solution for non-muscle-invasive bladder cancer, especially where first-line therapies have failed. #medicalinnovation #HIVEC #CombatCancer

12% of women have endometriosis, which slightly increases their risk of ovarian cancer. This risk is over 9 times higher in women with more severe endometriosis subtypes (deep infiltrating and endometriomas). #ovariancancerawarenessmonth #HIPEC #CombatCancer

Obesity not only increases the risk of ovarian cancer, but can also reduce survival rates. A 2023 study found obesity-mediated changes in the ovarian tumour immune microenvironment that impacts the response to chemo. 👉bit.ly/3NjRCgz #Ovariancancer #HIPEC #CombatCancer

The biggest risk factor for ovarian cancer is age. Risk starts rising steeply from around the age of 45, and it’s greatest in women aged 75-79, with 12% of all new cases diagnosed in this age group. #medicalinnovation #ovariancancerawarenessmonth #HIPEC #CombatCancer

We’ll be at @Uroweb's Annual Congress from Friday at Booth J22. Find out all about our FDA-approved trial, HIVEC®-HEAT, which aims to provide an affordable solution for non-muscle-invasive bladder cancer. #medicalinnovation #EAU26 #HIVEC #HIVECHEAT #CombatCancer

Lynch syndrome, Peut-Jeghers syndrome and mutations in the RAD51C, RAD51D, BRIP1 and PALB2 genes increase the risk of ovarian cancer. #ovariancancerawarenessmonth #ovariancancer #HIPEC #CombatCancer

Around 70% of women with BRCA1/BRCA2 mutations will develop breast cancer by the age of 80. These mutations also increase the risk of ovarian cancer – almost 45% of women with these mutations will develop ovarian cancer by age 80. #ovariancancerawarenessmonth #HIPEC

Ovarian cancer accounts for 2% of all cancer deaths and 5% of female cancer mortality in the UK. That’s 3,900 deaths every year – equivalent to 11 deaths a day. In the UK, the 5-year survival rate is below the European average. #ovariancancerawarenessmonth #HIPEC #CombatCancer

@CRUKresearch UK statistics show: ▶️ Ovarian cancer is the 6th most common in women ▶️ Incidence rates are highest in women aged 75-79 (28% of all new cases) ▶️ Incidence rates are forecast to rise by 5% by 2040 #ovariancancerawarenessmonth #HIPEC #CombatCancer

We’re looking forward to #EAU26 in London, March 13-16 🙂 Visit us at Booth J22 to find out more about our ongoing FDA-approved trial, #HIVEC®-HEAT, which aims to provide an affordable solution for NMIBC, especially where first-line therapies have failed. #CombatMedical

The last day of February is #RareDiseaseDay. A rare disease is one that affects <1 in 2000 – including 5 rare bladder cancers. We’re striving to improve outcomes for as many #bladdercancer patients as we can, using our Combat BRS for delivering #HIVEC® with MMC. CombatCancer

@UniOfYork researchers have found that direct communication between cells mediated by Cx32 protein can help maintain healthy urothelial tissue – potentially paving the way for new treatments for bladder cancer. 👉bit.ly/4rFcAFG #HIVEC #CombatCancer

Transurethral en bloc resection of bladder tumour significantly reduced 1-year recurrence rate in NMIBC vs standard resection, while the trial's multicentre design demonstrated ERBT's generalisability across different surgeons & centres. 👉bit.ly/4s6nh3H #CombatCancer